United Therapeutics Corporation (UTHR)

Market Cap	13.79B
Revenue (ttm)	2.88B
Net Income (ttm)	1.20B
Shares Out	44.91M
EPS (ttm)	24.64
PE Ratio	12.40
Forward PE	11.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,152
Open	309.58
Previous Close	308.02
Day's Range	304.85 - 308.32
52-Week Range	221.53 - 417.82
Beta	0.64
Analysts	Buy
Price Target	388.25 (+26.48%)
Earnings Date	Apr 30, 2025

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Analyst Forecast

According to 12 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is $388.25, which is an increase of 26.48% from the latest price.

Price Target

$388.25

(26.48% upside)

Analyst Consensus: Buy